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Abstract
Background and Objectives
Recent reports indicate that the incidence of nontuberculous mycobacterial-lung disease
(NTM-LD) is increasing. This study aimed to investigate the epidemiology and clinical fea-
tures of NTM-LD patients in Nagasaki prefecture, Japan to identify the negative prognostic
factors for NTM-LD in Japan.
Methods
The medical records of patients newly diagnosed with NTM-LD in eleven hospitals in Naga-
saki prefecture between January 2001 and February 2010 were reviewed. Data regarding
the annual population of each region and the incidence of all forms of tuberculosis were col-
lected to assess geographic variations in NTM-LD incidence, isolates, and
radiological features.
Results
A total 975 patients were diagnosed with NTM-LD. The incidence increased over the
study period and reached 11.0 and 10.1 per 100,000 population in 2008 and 2009, respec-
tively.M. intracellulare was the most common pathogen in the southern region, andM.
aviummost common in other regions. The most common radiographic pattern was the
nodular-bronchiectatic pattern. Age >60 years, body mass index <18.5 kg/m2, underlying
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lung disease, and cavitary pattern were the negative prognostic factors at the 1-year
follow-up.
Conclusions
The incidence of NTM-LD has been increasing in Nagasaki prefecture. The isolates and ra-
diographic features of patients vary markedly by region.
Introduction
Nontuberculous mycobacteria (NTM) are ubiquitous organisms that cause diverse types of in-
fectious disease in human organs, including lung, lymphatic, disseminated, skin, soft tissue,
and bone disease [1,2]. Several reports have suggested that the incidence of nontuberculous
mycobacterial lung disease (NTM-LD) has recently been increasing [1,3–6]. Although deter-
mining the precise incidence and prevalence of NTM-LD is difficult, the incidence in Japan
was estimated at 5.9 per 100,000 population in 2005 [7], which was higher than that of other
countries in the same year [4,6,8]. AlthoughMycobacterium species vary markedly by geo-
graphic region,Mycobacterium avium-intracellulare complex (MAC) has been reported as the
dominant species in NTM-LD [5,9]. In Japan,M. avium is most commonly isolated from the
respiratory tract, followed byM. intracellulare. Nevertheless, the species involved in NTM-LD
has been found to vary even within Japan [7].
Previous studies reported the several risk factors for NTM infection such as gastroesophage-
al reflux disease, chronic obstructive pulmonary disease (COPD), cystic fibrosis, history of tu-
berculosis and immune defects or diseases such as HIV infection, corticosteroid use [1,10].
Negative prognostic factors for HIV-negative patients with NTM-LD are high comorbidity
level, advanced age, male sex, fibrocavitary disease, body mass index (BMI)<18.5 kg/m2, and
anemia [11,12]. This study aimed to investigate the epidemiology and clinical features of
NTM-LD patients in Nagasaki prefecture to identify the risk factors and negative prognostic
factors in Japan.
Patients and Methods
Participants
Nagasaki prefecture provides approximately 14,700 hospital beds for the medical care of a pop-
ulation of approximately 1,500,000. The participants were selected by review of the microbio-
logical database at 11 hospitals (total 4,218 beds total) in the prefecture between January 2001
and February 2010. The participating facilities were Nagasaki University Hospital (862 beds),
Nagasaki Municipal Hospital (414 beds), Nagasaki Municipal Medical Center (217 beds), Japa-
nese Red Cross Nagasaki Genbaku Hospital (360 beds), Japanese Red Cross Nagasaki Genbaku
Isahaya Hospital (140 beds), Isahaya Health Insurance General Hospital (333 beds), National
Hospital Organization Nagasaki Medical Center (650 beds), Izumikawa Hospital (120 beds),
Sasebo City General Hospital (594 beds), Hokusho Central Hospital (224 beds), and Nagasaki
Goto Central Hospital (304 beds). The sputum, bronchial wash and tissue samples were cul-
tured using Ogawa egg-based media and/or a Mycobacteria Growth Indicator Tube (MGIT;
Becton Dickinson Microbiology Systems, Sparks, MD, USA). Isolated specimens were identified
using polymerase chain reaction (PCR) or DNA-DNA hybridization (DDH) forM. avium and
M. intracellulare; DDH forM. kansasii,M. abscessus,M. kansasii,M. gordonae,M. chelonae,
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M. szulgai,M. simiae,M. peregrinum,M. scrofulaceum andM. terrae; and 16S ribosomal RNA
sequencing forM. shimoidei [13,14]. Patients with at least two separate culture-positive sputum
samples or one culture-positive bronchial washing or lung tissue sample during the study peri-
od were included. Patients with a single positive sputum culture or PCR positive-culture nega-
tive samples were excluded.
Diagnosis of NTM-LD
Diagnosis was performed by specialists in infectious disease and/or respiratory medicine ac-
cording to 2007 American Thoracic Society (ATS)/Infectious Diseases Society of America
(IDSA) criteria [1]. In accordance with the criteria, patients with suspected infection with con-
taminated environmentalMycobacterium species were excluded from study participation. Pa-
tients who had been diagnosed with NTM-LD prior to the current study were also excluded.
Epidemiological Study
Among all the patients who had presented at the 11 hospitals during the study period, 975 had
been diagnosed with NTM-LD according to the 2007 ATS/IDSA criteria. After dividing the
prefecture into five regions on the basis of administrative boundaries and medical care zones,
the patients were classified into one region based on the residence listed in their medical rec-
ords. To estimate the annual incidence of NTM-LD in each region, data regarding the annual
population of each region were collected from the Nagasaki prefectural government, and data
regarding the incidence of all forms of tuberculosis collected from the healthcare center of each
region. In the analysis of the radiological features, 228 patients were excluded due to lack of ac-
curate information about chest computed tomography (CT) scan (Fig 1). Based on the review
of the results of chest CT scan, the remaining 747 patients were classified into four patterns ac-
cording to their radiological characteristics: the nodular-bronchiectatic (NB), cavitary (CAV),
hypersensitivity pneumonitis-like, or unclassifiable pattern. The NB pattern and CAV pattern
were defined by chest CT scan showing multifocal bronchiectasis with multiple small nodules
or cavitary opacities, respectively. If a patient had the characteristics of both the NB and CAV
patterns, the patient was classified in accordance with the dominant pattern. Using these data,
geographic variations in NTM-LD incidence, isolates, and radiological features were assessed.
Patient Characteristics and Prognostic Factors
Of the 975 patients, 374 were excluded from analysis due to lack of sufficient clinical informa-
tion in their medical records (Fig 1). The clinical course of the disease was assessed after 1 year
of diagnosis. Patient outcome was evaluated by review of (1) clinical, (2) radiological and (3)
microbiological responses. Clinical response was defined as resolution of symptoms such as
fever, weight loss, cough, sputum, hemoptysis and general fatigue. Radiological response was
defined as the clearing or improvement of opacity on chest radiographs/CT. Microbiological
response was determined by culturing of sputum. Patients who had shown improvement or no
change in the 3 factors and had experienced no deterioration were defined as having achieved
“stability”. Patients who had not met the criteria for “stability” definition and had subsequently
died from all causes were classified as having experienced “deterioration”.
Statistical Analysis
The data are presented as mean ± SD values. Statistical significance was evaluated using the
chi-square test or the two-tailed Mann-Whitney test, with the level of significance set at
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P< 0.05. All analyses were performed with GraphPad Prism 5.0 for Macintosh (GraphPad
Software, La Jolla, CA, USA).
Ethics Statement
This study was approved by the Ethical Committee of the Nagasaki University Hospital. As
this study was retrospective, and data were analyzed anonymously, the need to obtain patient
consent was waived by the committee.
Results
Fig 2A shows the numbers of NTM-LD patients newly diagnosed each year between 2001 and
2009, the population of Nagasaki prefecture, the incidence of all tuberculosis cases, and the esti-
mated incidence of NTM-LD between 2001 and 2009. As can be observed, 975 patients were
newly diagnosed with NTM-LD. Regarding the incidence by year, the NTM-LD incidence
gradually increased over the entire study period and especially in 2008 and 2009, when it
Fig 1. Flowchart of patient selection.
doi:10.1371/journal.pone.0128304.g001
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reached 11.0 and 10.1 per 100,000 population, respectively. The incidence was the highest in
the southeastern region of the prefecture, reaching 18.2 and 21.2 per 100,000 population in
2008 and 2009, respectively. Regarding the incidence by age, men and women>60 years ac-
counted for 83.8% of all patients, and the greatest increase in incidence occurred in men and
women>60 years and in women 45–59 years (Fig 2B and 2C).
Table 1 shows that the most frequently identified pathogen wasM. intracellulare (n = 432,
44.3%), followed byM. avium (n = 415, 42.6%),M. abscessus (n = 30, 3.1%),M. avium-intracel-
lulare complex (n = 24, 2.5%),M. kansasii (n = 20, 2.1%),M. gordonae (n = 20, 2.1%), and
other pathogens (n = 34, 3.5%). Although the incidence of infection withM. avium andM.
intracellulare particularly increased over the study period (Fig 3), the distribution of the isolates
varied throughout the prefecture, withM. intracellulare accounting for 77.5% of all the isolates
detected in the southern region (Fig 4). The most common radiographic pattern was the NB
pattern, which was observed in 591 cases (79.1%), followed by the CAV pattern, which as ob-
served in 134 cases (17.9%). No patients were found to have the hypersensitivity-like pattern.
Fig 2. Annual incidence of NTM-LD between 2001 and 2009 in Nagasaki, Japan. (A) Incidence of NTM-LD and all types of tuberculosis in all patients. (B)
Incidence in male patients. (C) Incidence in female patients.
doi:10.1371/journal.pone.0128304.g002
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The percentage of patients with each pattern was found to vary by region, especially in the
southern region, where CAV pattern was observed in 29.4% of the patients (Fig 5).
Of the 975 patients, the clinical information of 601 patients with a mean age of 71.2 ± 11.2
years was analyzed. Among these, 182 (30.3%) patients were male with a mean age of
73.0 ± 10.9 years and 419 (69.7%) female with a mean age of 70.5 ± 11.2 years. Regarding dis-
ease state, the underlying respiratory disease was identified in 89 (48.9%) male and 91 (21.7%)
female patients (Table 2) and systemic complications (diabetes, collagen disease, malignant dis-
ease other than lung cancer, chronic kidney disease, and chronic hepatic disease) in 52 (28.6%)
male and 87 (20.8%) female patients. The underlying disease in 53 (8.9%) patients was treated
by the administration of corticosteroids and/or immunosuppressants.
As observed in Table 3, which shows the causes of immunodeficiency, no patient was in-
fected with HIV. The NB pattern was the most common radiologic pattern, as observed in 479
(79.7%) of the 601 patients, followed by the CAV pattern in 94 (15.6%), and an unclassifiable
pattern in 28 (4.7%). The number of patients with the NB pattern increased over the study peri-
od, whereas the number with the CAV pattern remained unchanged. Regarding treatment, 279
(46.4%) patients had been treated by the administration of 1–5 anti-mycobacterial drugs within
3 months after diagnosis for a mean duration of 14.8 months, 214 (33.9%) patients had been
observed clinically without being administered medication for 1 year, and treatment data were
unavailable for 108 (18.0%) after 1 year (Fig 1). The analysis of prognostic factors was per-
formed with the 205 patients who had been followed up for at least 1 year after diagnosis. Of
the 86 patients (42.0%) who had improved, 75 (87.2%) had been treated with anti-mycobacteri-
al drugs and 11 (12.8%) had been treated with no medication. Poor prognostic factors were
found to be age>60 years, BMI<18.5 kg/m2, underlying lung disease, and radiographic CAV
pattern (Table 4).
Table 1. Isolates detected in 975 NTM-LD patients.
Isolate Number (%)
M. intracellulare 432 (44.3)
M. avium 415 (42.6)
M. abscessus 30 (3.1)
MAC 24 (2.5)
M. kansasii 20 (2.1)
M. gordonae 20 (2.1)
M. chelonae 7 (0.7)
M. fortuitum 3 (0.3)
M. szulgai 3 (0.3)
M. simiae 2 (0.2)
M. peregrinum 2 (0.2)
M. scrofulaceum 2 (0.2)
M. terrae 2 (0.2)
M. shimoidei* 1 (0.1)
PMI except for MAC 7 (0.7)
Not identified 5 (0.5)
MAC, Mycobacterium avium-intracellulare complex; PMI, polymicrobial infection
*Identified using 16S rRNA.
doi:10.1371/journal.pone.0128304.t001
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Discussion
NTM-LD has been increasing over the past few decades in many areas of the world [1,3–5,15].
The results of the present study revealed that the annual incidence of NTM-LD in Nagasaki
prefecture, Japan exceeded 10.0 per 100,000 population in 2008 and 2009. This incidence is
much higher than that of other developed countries over the past decade, which has been re-
ported as 2.7–5.6/100,000 in the United States [4,16,17], 0.72–0.74/100,000 in France [18], 0.9–
2.9/100,000 in the United Kingdom [19], 2.2–3.2/100,000 in Australia [6], 1.06–2.00/100,000
in Taiwan [8], and 1.08/100,000 in Denmark. The dynamics of NTM-LD may be affected by
various factors, including behavioral [12], cultural, genetic, environmental characteristics [20],
soil characteristics, income levels, and population densities [21,22]. In this study, men and
women>60 years old accounted for 83.8% of all participants, and the proportion of this age
group increased over the study period. This finding and those of previous reports [6,12,19] sug-
gest that the increasing incidence of NTM-LD could be associated with the aging of society and
the increasing number of patients with comorbidities. In addition, previous reports indicate
that cross-immunity and the protection provided by infection withM. tuberculosis and use of
the bacillus Calmette-Guerin (BCG) vaccine is associated with NTM infection [15,23–25]. Our
study also showed that the decreasing rate of tuberculosis is inversely associated with the in-
crease in NTM-LD. However, cross-immunity might not be a key component, since almost all
Japanese have been vaccinated with BCG for over half a century, and the southern prefecture,
which was found to have a high incidence of NTM-LD in this study, has been a moderately en-
demic area of tuberculosis (a constant incidence of 28.9–40.4/100,000) over the past decade.
Mycobacterium species are ubiquitous organisms present in water, soil, and room dust [26].
In this study,M. avium was the most commonly detected species in most regions of Nagasaki
prefecture, althoughM. intracellulare was the most commonly detected in the southern region.
This variation may be related to exposure to certain substances present in the soil that have
been associated with NTM infection [27,28]. In Australia, Chou et al. reported that the pres-
ence ofM. intracellulare infection was correlated with a shallower soil depth and agricultural
activities that lead to soil disturbance [22]. As the southern region of Nagasaki prefecture is an
Fig 3. Isolates detected in NTM-LD patients between 2001 and 2009 in Nagasaki, Japan.RGM, rapid
growing mycobacteria.
doi:10.1371/journal.pone.0128304.g003
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agricultural zone with soil well drained by an active volcano, in which the percentage of culti-
vated area to total area is twice as high as the average of the prefecture (26.5% vs. 12.3%), the
soil and agricultural activities performed within it might have led to differences in the domi-
nant isolate and high incidence in this region compared to that in other regions. Additionally,
in the southern region, the frequency of radiographic CAV pattern was higher than other
areas. As described above, high prevalence of tuberculosis might have led to high rate of
CAV pattern.
In general, effective treatment of NTM-LD requires long-term treatment with multiple anti-
mycobacterial drugs. ATS/IDSA guidelines recommend that patients with NTM-LD should be
treated until negative cultures are obtained for at least 1 year [1]. In addition to sputum culture,
assessment of symptom subscore [29], clinical symptoms [30], and radiological findings [30,31]
are useful in predicting clinical response. As short-term response to initial treatment has been
found to reflect long-term outcome [32], this study evaluated 1-year response by assessment of
clinical symptoms, radiological findings, and microbiological responses. The factors of age>60
years, BMI<18.5 kg/m2, underlying lung disease, and radiographic CAV pattern were found to
be poor prognostic factors, which accords with the findings of Hayashi et al. [11], who found
advanced age, systemic and/or respiratory comorbidities, non-NB radiographic features,
BMI<18.5 kg/m2, anemia, hypoalbuminemia, and erythrocyte sedimentation rate50 mm/h
Fig 4. Geographic variation in isolates detected in NTM-LD patients.Nine patients were residents of another prefecture. Map was obtained from the
Geospatial Information Authority of Japan (http://www.gsi.go.jp/ENGLISH/index.html). MAC,Mycobacterium avium-intracellulare complex.
doi:10.1371/journal.pone.0128304.g004
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Fig 5. Geographic variation in radiographic patterns in NTM-LD patients. Four patients were residents of another prefecture. NB, nodular-bronchiectatic
pattern; CAV, cavitary pattern.
doi:10.1371/journal.pone.0128304.g005
Table 2. Underlying respiratory diseases of NTM-LD.
Total Male Female P value
601 (%) 182 (%) 419 (%)
Underlying lung disease 189 (31.4) 90 (49.5) 99 (23.4) <0.0001
History of tuberculosis 81 (13.5) 35 (19.2) 46 (11.0) 0.0065
COPD 35 (5.8) 22 (12.1) 13 (3.1) <0.0001
Lung cancer 33 (5.5) 17 (9.3) 16 (3.8) 0.0063
Interstitial lung disease 24 (4.0) 13 (7.1) 11 (2.6) 0.0094
Fungal infection 15 (2.5) 9 (4.9) 6 (1.4) 0.0112
History of lung surgery 13 (2.2) 9 (4.9) 4 (1.0) 0.002
Bronchial asthma 11 (1.8) 4 (2.2) 7 (1.7) 0.6578
Chronic bronchitis 9 (1.5) 5 (2.7) 4 (1.0) 0.0964
Silicosis 8 (1.3) 8 (4.4) 0 (0.0) <0.0001
Bronchiectasis 2 (0.3) 1 (0.5) 1 (0.2) 0.5433
Pulmonary sarcoidosis 2 (0.3) 1 (0.5) 1 (0.2) 0.5433
COPD, Chronic Obstructive Pulmonary Disease.
doi:10.1371/journal.pone.0128304.t002
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to be negative prognostic factors for all-cause mortality of HIV-negative NTM-LD patients. It
also accords with those of Andréjak et al. [12], who found high comorbidity level, age>65
years, and male sex to be predictors of all-cause mortality for NTM-LD patients. Although it re-
mains unclear whether treatment of NTM-LD should be started immediately after diagnosis or
be delayed, these findings may be helpful in determining when to start treatment.
This study faced several limitations that should be considered when reviewing the findings.
Although a relatively large number of hospitals (11 hospitals) in Nagasaki prefecture were ex-
amined, not all NTM-LD cases in Nagasaki could be investigated. Second, the patients whose
sputum culture was NTM positive only once were excluded from further analysis. These limita-
tions might have led to underestimation of the incidence of NTM-LD. Third, the long-term
prognosis is not shown in this retrospective study since we could not obtain the sufficient data.
Additionally, selection bias may have been a factor in selecting the duration of treatment and
follow-up, specifically the selection of relatively brief treatment and follow-up periods. Howev-
er, as described above, short-term response for initial treatment has been reported to reflect
long-term outcome, so we believe that this study of prognostic factors 1 year after diagnosis
provides useful information.
In conclusion, the incidence of NTM-LD has been increasing over the past decade in Naga-
saki, Japan, a prefecture in which the isolates and radiographic patterns have varied markedly
by region. Among all possible factors, older age, BMI<18.5 kg/m2, underlying lung disease,
Table 3. Causes of immunodeficiency.
N = 601 (%)
Steroid administration 31 (5.2)
Methotrexate (MTX) administration 4 (0.7)
Immunosuppressant administration except MTX 8 (1.3)
Steroid and immunosuppressant administration 10 (1.7)
Diabetes 54 (9.0)
Collagen disease 30 (5.0)
Malignant disease 44 (7.3)
Chronic kidney disease 9 (1.5)
Chronic hepatic disease 22 (3.7)
doi:10.1371/journal.pone.0128304.t003
Table 4. Characteristics and 1-year prognosis of NTM-LD patients.
Total (%) Stability (%) Deterioration (%) P value
No. of patients 204 159 (77.9) 45 (22.1)
Age 69.9 ± 11.6 69.2 ± 11.0 73.3 ± 11.3 0.00315
Male/female 61/143 46/113 15/30 0.3243
BMI < 18.5 kg/m2 48 (23.5) 33 (20.8) 15 (33.3) 0.0355
CRP level (mg/dL) 0.85 ± 2.13 0.52 ± 1.21 1.49 ± 3.08 0.1431
Smoking pack-years  20 18 (8.8) 12 (7.5) 6 (13.3) 0.0582
CAM dose (mg) 565.2 ± 214.7 573.5 ± 192.0 542.9 ± 198.9 0.6369
Underlying lung disease* 65 (31.9) 45 (28.3) 20 (44.4) 0.0089
CAV 25 (12.3) 15 (9.4) 10 (22.2) 0.006
BMI, body mass index; CRP, C-reactive protein; CAM, clarithromycin; CAV, cavitary pattern on chest radiographs.
*Includes history of tuberculosis, chronic obstructive pulmonary disease, lung cancer, interstitial lung disease, asthma, and silicosis.
doi:10.1371/journal.pone.0128304.t004
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and radiographic CAV pattern appear to be negative prognostic factors in the deterioration of
patients with the disease.
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